New combination therapy safe, promising for melanoma patients

Jun 01, 2008

The combination of two different biotherapies may be beneficial for patients with inoperable melanoma, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Researchers in the melanoma and skin cancer program at UPCI combined two biotherapies – treatments that stimulate the immune system to fight cancer – and found the results promising in terms of anti-tumor effects and tolerable in terms of toxicity. High-dose interferon alfa-2b, a standard treatment for metastatic skin cancer, and tremelimumab, an antibody thought to instigate the body’s immune system to attack tumors, were combined for the first time in this phase 2 clinical trial.

“With each new study, we learn something important about melanoma,” said John M. Kirkwood, M.D., leader of the program and professor and vice chairman for clinical research in the Department of Medicine, University of Pittsburgh School of Medicine. “With this study, we learned that adding tremelimumab to traditional treatment is not only safe, but an effective way to induce an anti-tumor response, which is very exciting.”

For this study, 16 patients diagnosed with stage 4 melanoma, all of whom received and had not benefited from at least one round of previous therapy, were given the combination treatment. The overall response rate was 19 percent, and the study has since moved into the second stage, where it will enroll 21 additional patients.

Melanoma is a rare form of skin cancer, but it causes the majority of skin cancer-related deaths. Each year, approximately 160,000 new cases are diagnosed worldwide, and currently surgery is the only effective cure. For patients with inoperable disease, like those enrolled in this study, discovering a safe and effective treatment is vital.

Source: University of Pittsburgh

Explore further: ACG: Recent increase in incidence of young-onset CRC

add to favorites email to friend print save as pdf

Related Stories

Pharmaceuticals and the water-fish-osprey food web

2 hours ago

Ospreys do not carry significant amounts of human pharmaceutical chemicals, despite widespread occurrence of these chemicals in water, a recent U.S. Geological Survey (USGS) and Baylor University study finds. ...

Cold Atom Laboratory creates atomic dance

2 hours ago

Like dancers in a chorus line, atoms' movements become synchronized when lowered to extremely cold temperatures. To study this bizarre phenomenon, called a Bose-Einstein condensate, researchers need to cool ...

Recommended for you

ACG: Recent increase in incidence of young-onset CRC

38 minutes ago

(HealthDay)—The incidence of young-onset colorectal cancer (CRC) is increasing, and the disease is more aggressive pathologically. These findings are being presented at the annual meeting of the American ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

E_L_Earnhardt
not rated yet Jun 01, 2008
Nearly all "cancers" result from accelerated mitosis, which involves ENERGY, (ie high-speed electrons). "Freezing" kills any cell, (robbing it of energy). "Cooling", (decreasing electron speed & energy), slows mitosis, arrests cancer!